Literature DB >> 7491559

Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients.

C A Wong1, F Donald, J T Macfarlane.   

Abstract

BACKGROUND: Streptococcus milleri is increasingly being recognised as an important pulmonary pathogen which may lead to the development of empyema or lung abscess. Although several small series have been reported, the clinical and laboratory features have yet to be fully characterised.
METHODS: Twenty five cases were identified and the clinical and laboratory data from case records were analysed.
RESULTS: There were 16 empyemas, five lung abscesses, and four with both lung abscess and empyema. The mean age of the patients was 61 years (range 36-89) and 84% were men. The most common symptoms at presentation were shortness of breath, chest pain, cough, and weight loss; only 36% had a fever. Four of the nine patients with lung abscess required a diagnostic lobectomy because of suspected malignancy. Predisposing factors were present in 80% of patients and included the following: pneumonia, periodontal disease, excess alcohol intake, previous thoracic surgical procedures, and malignancy. Laboratory features of S milleri infection were leucocytosis, neutrophilia, anaemia, abnormal liver function tests, and hypoalbuminaemia. In the group with empyema five patients had a pneumothorax on initial presentation and pleural loculation occurred in 10 of these patients. The median stay in hospital was 34 days (range 11-88). Six patients died, five of whom had significant underlying illnesses.
CONCLUSIONS: Pulmonary infection with S milleri may result in considerable morbidity and mortality, and is characterised by a strong male predominance, non-specific symptoms (often without toxicity), the presence of predisposing factors, pleural loculation, pneumothorax, and a protracted stay in hospital.

Entities:  

Mesh:

Year:  1995        PMID: 7491559      PMCID: PMC475024          DOI: 10.1136/thx.50.10.1093

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

1.  Management of acute empyema.

Authors:  D W Moores
Journal:  Chest       Date:  1992-11       Impact factor: 9.410

2.  Immediate drainage is not required for all patients with complicated parapneumonic effusions.

Authors:  H A Berger; M L Morganroth
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

3.  Occurrence and cultural features of Streptococcus milleri in various body sites.

Authors:  P M Poole; G Wilson
Journal:  J Clin Pathol       Date:  1979-08       Impact factor: 3.411

4.  Hyaluronidase production in Streptococcus milleri in relation to infection.

Authors:  P F Unsworth
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

5.  Clinical significance of Streptococcus milleri.

Authors:  P Van der Auwera
Journal:  Eur J Clin Microbiol       Date:  1985-08       Impact factor: 3.267

6.  A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection: synergy with an anaerobe.

Authors:  T Shinzato; A Saito
Journal:  J Med Microbiol       Date:  1994-02       Impact factor: 2.472

7.  Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema.

Authors:  D Bouros; S Schiza; P Panagou; J Drositis; N Siafakas
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

8.  Physiological differentiation of viridans streptococci.

Authors:  R R Facklam
Journal:  J Clin Microbiol       Date:  1977-02       Impact factor: 5.948

9.  Infections due to Lancefield group F and related Streptococci (S. milleri, S. anginosus).

Authors:  D M Shlaes; P I Lerner; E Wolinsky; K V Gopalakrishna
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

10.  Emended descriptions and recognition of Streptococcus constellatus, Streptococcus intermedius, and Streptococcus anginosus as distinct species.

Authors:  R A Whiley; D Beighton
Journal:  Int J Syst Bacteriol       Date:  1991-01
View more
  21 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Pyopneumothorax due to Streptococcus milleri.

Authors:  Philipp Eller; Igor Theurl; Florian Koppelstaetter; Guenter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Multiple lung abscesses secondary to a uterine empyema caused by an intrauterine device.

Authors:  M van Laren; N C van Walree; J A J W Kluytmans
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

4.  Rapid developing empyema by group F beta Streptococcus anginosus group.

Authors:  Muhammad Azharuddin; Dy Prudence; Prem Shanker Shukla; Ajay Mathur
Journal:  BMJ Case Rep       Date:  2017-07-13

5.  Ring lesions in the brain: a harmless commensal?

Authors:  Justin Garner; Robin Howard
Journal:  BMJ Case Rep       Date:  2013-04-16

6.  Pyopneumothorax secondary to Streptococcus milleri infection.

Authors:  Mohd Jazman Che Rahim; Nurashikin Mohammad; Wan Syamimee Wan Ghazali
Journal:  BMJ Case Rep       Date:  2016-11-23

7.  Unusual case of a giant lung abscess initially misdiagnosed and treated as an empyema.

Authors:  Joana Sofia Carvalho; Diogo Paixão Marques; Inês Oliveira; Ana Cláudia Vieira
Journal:  BMJ Case Rep       Date:  2019-05-10

8.  Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.

Authors:  Margot E Grinwis; Christopher D Sibley; Michael D Parkins; Christina S Eshaghurshan; Harvey R Rabin; Michael G Surette
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

9.  Synchronous bilateral VATS decortication for paediatric bilateral empyema.

Authors:  S Sivasubramanian; V Hjortdal; G A Cohen
Journal:  Pediatr Surg Int       Date:  2004-06-17       Impact factor: 1.827

Review 10.  The role of Streptococcus intermedius in brain abscess.

Authors:  A K Mishra; P-E Fournier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-28       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.